Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PD-1/PD-L1 inhibitor

- PMLiVE

First Boehringer and now Merck ‘gamifies’ clinical research

Kaggle challenge set up to help pharma company develop safe and effective medicines

- PMLiVE

Merck misses revenue targets as Singulair slumps

Asthma drug hit hard by generic competition in the US

- PMLiVE

Merck & Co pays €110m upfront for AiCuris’ CMV portfolio

Lead candidate is orphan drug letermovir for transplant patients

- PMLiVE

Merck says osteoporosis drug clears phase II trial

Odanacatib on track for 2013 filing

- PMLiVE

Merck & Co relocates global headquarters

Leaves Whitehouse Station for new site in New Jersey

- PMLiVE

Merck & Co says Januvia follow-up looking good

Diabetes drug shows promise in phase II as once-weekly treatment

- PMLiVE

Janssen and Merck & Co share UK Prix Galien for hepatitis C drugs

Incivo and Victrelis joint winners of Innovative Product Award

- PMLiVE

Janssen and Merck & Co share UK Prix Galien for hepatitis C drugs

Incivo and Victrelis joint winners of Innovative Product Award

Merck’s new insomnia drug clears phase III trial

Novel method of treatment offers fewer side effects

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links